{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:41:00Z","timestamp":1777329660869,"version":"3.51.4"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.16091","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T16:31:09Z","timestamp":1574440269000},"page":"e1916091","source":"Crossref","is-referenced-by-count":17,"title":["Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib"],"prefix":"10.1001","volume":"2","author":[{"given":"Lelia Maria","family":"de Almeida Carvalho","sequence":"first","affiliation":[{"name":"Hospital das Cl\u00ednicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"de Oliveira Sapori Avelar","sequence":"additional","affiliation":[{"name":"Hospital das Cl\u00ednicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Division of Hematology Oncology, Oregon Health and Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Gill","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Division of Hematology Oncology, Oregon Health and Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Division of Hematology Oncology, Oregon Health and Science University, Portland"},{"name":"Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland"},{"name":"Center for Health Care Ethics, Oregon Health and Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2019,11,22]]},"reference":[{"issue":"4","key":"zoi190612r2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma.","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi190612r4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing.","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5","key":"zoi190612r6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"key":"zoi190612r7","doi-asserted-by":"publisher","first-page":"k668","DOI":"10.1136\/bmj.k668","article-title":"Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.","volume":"360","author":"Wagner","year":"2018","journal-title":"BMJ"},{"key":"zoi190612r8","author":"Oregon Health and Science University"},{"issue":"8","key":"zoi190612r10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology.","volume":"4","author":"Marquart","year":"2018","journal-title":"JAMA Oncol"},{"issue":"5","key":"zoi190612r11","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs.","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi190612r12","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.6004\/jnccn.2017.7030","article-title":"Pazopanib sensitivity in a patient with breast cancer and FGFR1 amplification.","volume":"15","author":"Cheng","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"zoi190612r13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13058-017-0807-8","article-title":"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.","volume":"19","author":"Musolino","year":"2017","journal-title":"Breast Cancer Res"},{"issue":"11","key":"zoi190612r14","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1093\/annonc\/mdu390","article-title":"Phase I\/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.","volume":"25","author":"Soria","year":"2014","journal-title":"Ann Oncol"},{"issue":"13","key":"zoi190612r15","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","article-title":"Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.","volume":"19","author":"Andr\u00e9","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"4","key":"zoi190612r16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11523-017-0502-9","article-title":"A phase 1 study of LY2874455, an oral selective pan-FGFR inhibitor, in patients with advanced cancer.","volume":"12","author":"Michael","year":"2017","journal-title":"Target Oncol"},{"issue":"2","key":"zoi190612r17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","article-title":"Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study.","volume":"35","author":"Nogova","year":"2017","journal-title":"J Clin Oncol"},{"issue":"19","key":"zoi190612r18","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1002\/cncr.v122.19","article-title":"Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: a single-arm, phase 2 study.","volume":"122","author":"Lim","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"zoi190612r19","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a002089","article-title":"Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer.","volume":"4","author":"Dhami","year":"2018","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"30","key":"zoi190612r20","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I dose-escalation study of JNJ-42756493, an oral pan\u2013fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors.","volume":"33","author":"Tabernero","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi190612r21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ygyno.2014.10.001","article-title":"A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology\/Gynecologic Oncology Group Study.","volume":"135","author":"Dizon","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"1","key":"zoi190612r22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2014.07.083","article-title":"A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology\/Gynecologic Oncology Group Study.","volume":"135","author":"Powell","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"9","key":"zoi190612r23","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1158\/1078-0432.CCR-11-1900","article-title":"A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.","volume":"18","author":"Mross","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"7","key":"zoi190612r24","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00432-016-2161-0","article-title":"Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.","volume":"142","author":"Sch\u00e4fer","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"issue":"14","key":"zoi190612r25","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-14-2199","article-title":"Detection, characterization, and inhibition of FGFR\u2013TACC fusions in IDH wild-type glioma.","volume":"21","author":"Di Stefano","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"zoi190612r26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11060-014-1631-y","article-title":"Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.","volume":"121","author":"Norden","year":"2015","journal-title":"J Neurooncol"},{"issue":"2","key":"zoi190612r27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11060-012-1009-y","article-title":"Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme.","volume":"111","author":"Muhic","year":"2013","journal-title":"J Neurooncol"},{"issue":"1","key":"zoi190612r28","doi-asserted-by":"crossref","first-page":"e00383","DOI":"10.1002\/rcr2.383","article-title":"Gastric perforation related to concurrent use of nintedanib and ramucirumab.","volume":"7","author":"Takahashi","year":"2018","journal-title":"Respirol Case Rep"},{"issue":"6","key":"zoi190612r29","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/annonc\/mdx107","article-title":"A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.","volume":"28","author":"Van Cutsem","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"zoi190612r30","doi-asserted-by":"crossref","first-page":"15014","DOI":"10.18632\/oncotarget.14788","article-title":"Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"zoi190612r31","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1158\/1535-7163.MCT-15-0230","article-title":"Tumors with AKT1E17K mutations are rational targets for single agent or combination therapy with AKT inhibitors.","volume":"14","author":"Davies","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"zoi190612r32","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-13-3006","article-title":"Phase II results of dovitinib (TKI258) in patients with metastatic renal cell cancer.","volume":"20","author":"Escudier","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"5","key":"zoi190612r33","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1158\/1078-0432.CCR-12-2885","article-title":"Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.","volume":"19","author":"Angevin","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"7","key":"zoi190612r34","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1093\/annonc\/mdq237","article-title":"FGFR inhibitor induced peripheral neuropathy in patients with advanced RCC.","volume":"21","author":"Loriot","year":"2010","journal-title":"Ann Oncol"},{"issue":"3","key":"zoi190612r35","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma.","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"key":"zoi190612r36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fonc.2018.00045","article-title":"Clinical benefit of pazopanib in a patient with metastatic chondrosarcoma: a case report and review of the literature.","volume":"8","author":"Tsavaris","year":"2018","journal-title":"Front Oncol"},{"issue":"10","key":"zoi190612r37","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/cup.2018.45.issue-10","article-title":"Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor.","volume":"45","author":"Arudra","year":"2018","journal-title":"J Cutan Pathol"},{"issue":"23","key":"zoi190612r38","doi-asserted-by":"publisher","first-page":"7451","DOI":"10.1158\/1078-0432.CCR-11-1747","article-title":"Phase I\/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.","volume":"17","author":"Kim","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"2","key":"zoi190612r39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.5306\/wjco.v7.i2.253","article-title":"Off-label use of targeted therapies in oncology.","volume":"7","author":"Lev\u00eaque","year":"2016","journal-title":"World J Clin Oncol"},{"issue":"2","key":"zoi190612r40","doi-asserted-by":"publisher","first-page":"2S","DOI":"10.1378\/chest.95.2_Supplement.2S","article-title":"Rules of evidence and clinical recommendations on the use of antithrombotic agents.","volume":"95","author":"Sackett","year":"1989","journal-title":"Chest"},{"issue":"12","key":"zoi190612r41","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1002\/cam4.v8.12","article-title":"Are 90% of deaths from cancer caused by metastases?","volume":"8","author":"Dillek\u00e5s","year":"2019","journal-title":"Cancer Med"},{"issue":"3","key":"zoi190612r42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/jcpt.2017.42.issue-3","article-title":"Off-label drug use in oncology: a systematic review of literature.","volume":"42","author":"Saiyed","year":"2017","journal-title":"J Clin Pharm Ther"},{"issue":"7619","key":"zoi190612r44","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1038\/537S63a","article-title":"Perspective: the precision-oncology illusion.","volume":"537","author":"Prasad","year":"2016","journal-title":"Nature"},{"issue":"13","key":"zoi190612r45","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMsb1607705","article-title":"Limits to personalized cancer medicine.","volume":"375","author":"Tannock","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi190612r46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1053\/j.seminoncol.2016.01.005","article-title":"Precision oncology: a strategy we were not ready to deploy.","volume":"43","author":"Fojo","year":"2016","journal-title":"Semin Oncol"},{"issue":"2","key":"zoi190612r47","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/S1470-2045(15)00620-8","article-title":"Precision oncology: origins, optimism, and potential.","volume":"17","author":"Prasad","year":"2016","journal-title":"Lancet Oncol"},{"key":"zoi190612r9","volume-title":"Cancer Facts and Figures 2019","author":"American Cancer Society","year":"2019"},{"key":"zoi190612r1","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma. Accessed October 16, 2019."},{"key":"zoi190612r3","unstructured":"Janssen Pharmaceutical Companies. Balversa (erdafitinib). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212018s000lbl.pdf. Accessed June 4, 2019."},{"key":"zoi190612r5","unstructured":"Janssen Scientific Affairs. Expanded access program (EAP) for participants with advanced cancers and fibroblast growth factor receptor (FGFR) genetic alterations who have exhausted all treatment options. https:\/\/ClinicalTrials.gov\/show\/NCT03825484. Accessed October 16, 2019."},{"key":"zoi190612r43","unstructured":"HanDH. First-in-class, targeted therapy approved for metastatic bladder cancer. https:\/\/www.cancertherapyadvisor.com\/home\/cancer-topics\/bladder-cancer\/balversa-fda-approval-bladder-cancer-treamtment-risk\/. Accessed October 16, 2019."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2755870\/de_almeida_carvalho_2019_oi_190612.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T19:18:08Z","timestamp":1665083888000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2755870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,22]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.16091","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,22]]}}}